Priority Review for Roche's Tecentriq in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA accepted and granted Priority Review to an sBLA for Tecentriq atezolizumab in combination with Avastin bevacizumab, paclitaxel and carboplatin

Read the full 291 word article

User Sign In